newsfilter
← Latest News
GlobeNewswire·

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Dose-finding Phase 1b study (n=240) on track for topline data in September 2026CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1 classCRB-913 yielded